Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    16707611 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel;   Drug: Trastuzumab, Docetaxel, Bevacizumab;   Drug: Trastuzumab+Docetaxel+NPLD;   Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
2 Terminated
Has Results
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Docetaxel;   Drug: CPT-11;   Drug: Paclitaxel;   Drug: Vinorelbine Tartrate;   Drug: Gemcitabine

Indicates status has not been verified in more than two years